ClinicalTrials.gg
Status unknownNCT02732691Updated Nov 22, 2022Results posted

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

An interventional study of JenaValve Pericardial TAVR System in Aortic Valve Stenosis, Heart Valve Diseases and Heart Diseases, sponsored by JenaValve Technology, Inc.. Status unknown at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-22.

Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
72nd of 93
68 · median 220
Started
2016
with 12 others
No phase
82 of 191
13 open now
Registered
75th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 72nd largest by enrollment of the 93 interventional ones that give a count, is one of 13 that started in 2016, is one of 82 with no phase, and was the 75th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

To collect information about treatment for severe aortic stenosis (AS), which affects the aortic valve in the heart. Aortic stenosis is a narrowing of the aortic valve opening, which decreases blood flow from the heart and causes symptoms such as chest pain, fainting and shortness of breath. The preferred treatment for severe aortic stenosis is aortic valve replacement surgery.

Read the detailed description

This study will examine the use of a TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. This less invasive surgical approach called TAVR is offered to those patients who are high risk for undergoing open heart surgery to replace the aortic valve. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System.

03

Conditions studied

  • Aortic Valve Stenosis
  • Heart Valve Diseases
  • Heart Diseases
  • Cardiovascular Diseases
  • Ventricular Outflow Obstruction

Keywords

  • Valvular Heart Disease
  • Critical/Severe Aortic Stenosis
  • High risk symptomatic patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with severe degenerative native aortic stenosis (AS).
  • Patient at high risk for open surgical valve replacement
  • Patient symptomatic according to functional class II or higher

Exclusion criteria

Exclusion Criteria:

  • Congenital uni- or bicuspid aortic valve morphology
  • Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  • Endocarditis or other active infection
  • Need for urgent or emergent TAVR procedure for any reason
  • Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Transcatheter Aortic Valve Replacement (TAVR)

    Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.

    Device: JenaValve Pericardial TAVR System

Interventions

  • DeviceJenaValve Pericardial TAVR System

    Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.

06

What researchers measure

Primary outcomes

  1. All-Cause Mortality

    All-cause mortality rate at 30 Day

    Time frame: 30 Day

Secondary outcomes

  1. Myocardial Infarction

    Peri-procedural and spontaneous myocardial infarction

    Time frame: 30 Day

  2. All Stroke/TIA

    Neurological Complications

    Time frame: 30 Day

  3. Major Bleeding

    Life threatening or major bleeding

    Time frame: 30 Day

  4. Major Vascular Complication

    Major vascular and bleeding complications

    Time frame: 30 Day

  5. Conduction Disturbance and Arrhythmias

    Conduction system injury (defect), including AV block, which may require a permanent pacemaker

    Time frame: 30 Day

  6. Acute Kidney Injury (AKI)

    Number of patients who were diagnosed with AKI Stage 2 or 3: AKI Stage 2: Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR urine output \<0.5 mL/kg/h for \>12 but \<24 h AKI Stage 3: Increase in serum creatinine to ≥300% (\>3 × increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR urine output \<0.3 ml/kg/h for ≥24 h OR anuria for ≥12 h

    Time frame: 30 Day

  7. Coronary Obstruction Requiring Intervention

    Coronary obstruction post-implant requiring intervention

    Time frame: 30 Day

  8. Endocarditis

    Bacterial endocarditis

    Time frame: 30 Day

  9. Conversion to Surgical Aortic Valve Replacement (SAVR)

    Number of patients who underwent conversion to open sternotomy during the TAVR procedure secondary to any procedure-related complications

    Time frame: 30 Day

  10. THV Malpositioning

    Number of patients who experienced: Migration: After initial correct positioning, the valve prosthesis moves upwards or downwards, within the aortic annulus from its initial position, with or without consequences Embolization: The valve prosthesis moves during or after deployment such that it loses contact with the aortic annulus Ectopic Valve Deployment: Permanent deployment of the valve prosthesis in a location other than the aortic root

    Time frame: 30 Day

07

Results

Posted Nov 22, 2022

Participant flow

Participant flow — Overall Study
MilestoneTranscatheter Aortic Valve Replacement (TAVR)
Started68
Completed68
Not completed0

Outcome measures

PrimaryAll-Cause Mortality

All-cause mortality rate at 30 Day

Time frame:
30 Day
Reported as:
Count of participants · Participants
All-Cause Mortality
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
All-Cause Mortality2
SecondaryMyocardial Infarction

Peri-procedural and spontaneous myocardial infarction

Time frame:
30 Day
Reported as:
Count of participants · Participants
Myocardial Infarction
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Myocardial Infarction1
SecondaryAll Stroke/TIA

Neurological Complications

Time frame:
30 Day
Reported as:
Count of participants · Participants
All Stroke/TIA
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
All Stroke/TIA6
SecondaryMajor Bleeding

Life threatening or major bleeding

Time frame:
30 Day
Reported as:
Count of participants · Participants
Major Bleeding
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Major Bleeding4
SecondaryMajor Vascular Complication

Major vascular and bleeding complications

Time frame:
30 Day
Reported as:
Count of participants · Participants
Major Vascular Complication
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Major Vascular Complication5
SecondaryConduction Disturbance and Arrhythmias

Conduction system injury (defect), including AV block, which may require a permanent pacemaker

Time frame:
30 Day
Reported as:
Count of participants · Participants
Conduction Disturbance and Arrhythmias
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Conduction Disturbance and Arrhythmias10
SecondaryAcute Kidney Injury (AKI)

Number of patients who were diagnosed with AKI Stage 2 or 3: AKI Stage 2: Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR urine output \<0.5 mL/kg/h for \>12 but \<24 h AKI Stage 3: Increase in serum creatinine to ≥300% (\>3 × increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR urine output \<0.3 ml/kg/h for ≥24 h OR anuria for ≥12 h

Time frame:
30 Day
Reported as:
Count of participants · Participants
Acute Kidney Injury (AKI)
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Acute Kidney Injury (AKI)0
SecondaryCoronary Obstruction Requiring Intervention

Coronary obstruction post-implant requiring intervention

Time frame:
30 Day
Reported as:
Count of participants · Participants
Coronary Obstruction Requiring Intervention
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Coronary Obstruction Requiring Intervention0
SecondaryEndocarditis

Bacterial endocarditis

Time frame:
30 Day
Reported as:
Count of participants · Participants
Endocarditis
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Endocarditis0
SecondaryConversion to Surgical Aortic Valve Replacement (SAVR)

Number of patients who underwent conversion to open sternotomy during the TAVR procedure secondary to any procedure-related complications

Time frame:
30 Day
Reported as:
Count of participants · Participants
Conversion to Surgical Aortic Valve Replacement (SAVR)
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
Conversion to Surgical Aortic Valve Replacement (SAVR)1
SecondaryTHV Malpositioning

Number of patients who experienced: Migration: After initial correct positioning, the valve prosthesis moves upwards or downwards, within the aortic annulus from its initial position, with or without consequences Embolization: The valve prosthesis moves during or after deployment such that it loses contact with the aortic annulus Ectopic Valve Deployment: Permanent deployment of the valve prosthesis in a location other than the aortic root

Time frame:
30 Day
Reported as:
Count of participants · Participants
THV Malpositioning
ParticipantsTranscatheter Aortic Valve Replacement (TAVR)
THV Malpositioning3

Adverse events

Collected over 30 day. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Transcatheter Aortic Valve Replacement (TAVR)2/68 (2.9%)39/68 (57.4%)23/68 (33.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventTranscatheter Aortic Valve Replacement (TAVR)
Other InfectionInfections and infestations8/68
Bleeding ComplicationBlood and lymphatic system disorders5/68
Conduction DisturbanceCardiac disorders5/68
Stroke/TIANervous system disorders4/68
Bleeding (Major)Blood and lymphatic system disorders3/68
GI ComplicationGastrointestinal disorders3/68
Heart FailureCardiac disorders3/68
PneumoniaInfections and infestations3/68
Arterial OcclusionCardiac disorders2/68
Exacerbation COPDRespiratory, thoracic and mediastinal disorders2/68
Most frequent other events
Most frequent other events
EventTranscatheter Aortic Valve Replacement (TAVR)
OtherGeneral disorders17/68
Bleeding ComplicationBlood and lymphatic system disorders5/68
Respiratory ComplicationRespiratory, thoracic and mediastinal disorders5/68
Chest PainGeneral disorders4/68

Baseline characteristics

Enrolled

Age, Continuous
Age, Continuous(years)Transcatheter Aortic Valve Replacement (TAVR)
Mean83 ± 5
Sex: Female, Male
Sex: Female, Male(Participants)Transcatheter Aortic Valve Replacement (TAVR)
Female44
Male24
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Transcatheter Aortic Valve Replacement (TAVR)
08

Study locations

13 sites
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Deutsches Herzzentrum Berlin
    Berlin, 13353, Germany
  • Universitäts-Herzzentrum Freiburg/Bad Krozingen
    Freiburg, 79106, Germany
  • Universitätsklinikum Halle
    Halle (Saale), 6120, Germany
  • Universitäres Herzzentrum Hamburg
    Hamburg, 20246, Germany
  • Herzzentrum der Universität zu Köln
    Köln, 50937, Germany
  • Robert-Bosch-Krankenhaus
    Stuttgart, 70376, Germany
  • Leiden University Medical Center
    Leiden, 2333, Netherlands
  • St. Antonius Hospital
    Nieuwegein, 3435, Netherlands
  • Erasmus University Medical Center
    Rotterdam, 3062, Netherlands
  • Auckland City Hospital
    Auckland, 1142, New Zealand
  • Waikato Hospital
    Hamilton, 3240, New Zealand
09

References and documents

Publications

  • Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14. No abstract available. PubMed 28314623 ↗
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15. No abstract available. PubMed 28298458 ↗
  • Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43. doi: 10.1016/s0195-668x(03)00201-x. PubMed 12831818 ↗
  • Hamid N, Ranard LS, Khalique OK, Hahn RT, Nazif TM, George I, Ng V, Leon MB, Kodali SK, Vahl TP. Commissural Alignment After Transfemoral Transcatheter Aortic Valve Replacement With the JenaValve Trilogy System. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2079-2081. doi: 10.1016/j.jcin.2021.07.025. No abstract available. PubMed 34556282 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in May 2019, 31 months.

Results were first posted in Nov 2022, 3 years 5 months after primary completion.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 31 months is close to that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2016
First posted
Apr 11, 2016
StartActual
Oct 21, 2016
Primary completionActual
May 28, 2019
CompletionEst.
Apr 2024
Results first posted
Nov 22, 2022
Last update
Nov 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02732691
Lead sponsor
JenaValve Technology, Inc.
Responsible party
Sponsor
First posted
Apr 11, 2016
Start date
Oct 21, 2016
Primary completion
May 28, 2019
Completion
Apr 2024 (estimated)
Results posted
Nov 22, 2022
Last update
Nov 22, 2022

Study contacts

Martin B Leon, MD
study chair · New York-Presbyterian Hospital/Columbia University Medical Center, USA
Torsten P Vahl, MD
principal investigator · New York-Presbyterian Hospital/Columbia University Medical Center, USA
Vinod H Thourani, MD
principal investigator · Piedmont Heart Institute, USA
Hendrik Treede, MD
principal investigator · University Hospital Bonn, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion